PDAC-001
Pancreatic Ductal Adenocarcinoma · KRAS/SMAD4/TP53 Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · GI-ONCOLOGY← RESEARCH
Pancreatic Ductal Adenocarcinoma
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
FOLFIRINOX Metastatic PROVEN
OS 11.1 vs 6.8mo gemcitabine. Standard fit metastatic.
Conroy 2011 NEJM
Gem+Nab-Paclitaxel PROVEN
OS 8.5 vs 6.7mo. Alternative or less fit.
Von Hoff 2013 NEJM
Olaparib BRCA POLO PROVEN
BRCA germline PDAC. PFS 7.4 vs 3.8mo maintenance.
Golan 2019 NEJM POLO
MSI-H → Pembrolizumab OPEN
Only 1% PDAC MSI-H. 100% checkpoint-sensitive. Screen all.
Le 2017 Science
KRAS G12D Inhibitors OPEN
MRTX1133 Phase I. Higher primary resistance than NSCLC G12C.
Fell 2020 J Med Chem
Open Sorries — Click to Expand
S-1 SORRY-1 · KRAS G12D No Inhibitor
S-2 SORRY-2 · Desmoplastic Stroma
S-3 SORRY-3 · Late Detection
S-4 SORRY-4 · CA19-9 Lewis Antigen-Negative
S-5 SORRY-5 · KRAS G12C Less Effective in PDAC
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
PDAC-001 · HARDEST SORRY · KRAS G12D UNDRUGGABLE · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693